Skip to content
Tariffs and dutiesCommerce BISUnited StatesExports

Guidance and Procedures for Implementing Tariff Adjustments for Specialty Pharmaceuticals and Associated Pharmaceutical Ingredients and Technical Corrections to the Harmonized Tariff Schedule of the United States for Duties Imposed Under Proclamation 11020

23 September 2026

In plain English

CBP guidance implements Proclamation 11020, setting a zero ad valorem tariff for specialty pharmaceuticals and ingredients from eligible jurisdictions and correcting the HTSUS accordingly.

Read the official notice
Topic
Tariffs and duties
Regulator
Commerce BIS
Published
23 September 2026
For
Exports
Where it applies
United States
Source
BIS (Bureau of Industry and Security)

From the notice

This notice defines the pharmaceutical products and lists the jurisdictions that are eligible to receive an ad valorem tariff rate of zero pursuant to Presidential Proclamation 11020 of April 2, 2026, "Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States," (Proclamation 11020). These pharmaceutical products include drugs and associated ingredients where all approved indications are designated as orphan; nuclear medicines; plasma derived therapies; fertili
The full text is at the source

Olive tells you which of these hit your products.

Olive reads every change like these against your own products, codes and trade lanes, whether you import, export or both, and drafts the update to your compliance program for your approval. Nothing changes without you.

Get startedLive demo

Olivra lists official notices for information only. It is not legal advice, and Olive is not a lawyer or a licensed customs broker. The official text at the source is what counts.

More from Commerce BIS

See everything Olive monitors